Edotreotide (BioDeep_00000804711)
代谢物信息卡片
N-Acetyl-Lys-Octreotide
化学式: C65H92N14O18S2 (1420.6155132000001)
中文名称: 奥曲肽杂质2
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CO)C(C)O)O
InChI: InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
描述信息
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C62799 - Somatostatin Receptor Agonist
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals
Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer[1].
同义名列表
5 个代谢物同义名
N-Acetyl-Lys-Octreotide; Edotreotide; DOTATOC; SDZ-SMT 487; SMT 487
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 158782
- ChEMBL: CHEMBL408350
- CAS: 204318-14-9
- CAS: 173606-11-6
- medchemexpress: HY-106033
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Caroline Boursier, Elodie Chevalier, Laura Filippetti, Laetitia Imbert, Veronique Roch, Olivier Huttin, Marine Claudin, Pierre-Yves Marie. 68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination.
European journal of nuclear medicine and molecular imaging.
2022 03; 49(4):1433-1434. doi:
10.1007/s00259-021-05609-4. [PMID: 34746968] - Clemens Kratochwil, Leonidas Apostolidis, Hendrik Rathke, Christos Apostolidis, Felix Bicu, Frank Bruchertseifer, Peter L Choyke, Uwe Haberkorn, Frederik L Giesel, Alfred Morgenstern. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.
European journal of nuclear medicine and molecular imaging.
2021 12; 49(1):54-63. doi:
10.1007/s00259-021-05474-1. [PMID: 34448031] - Marija Z Jeremic, Milovan D Matovic, Dragana Z Krstic, Suzana B Pantovic, Dragoslav R Nikezic. A five-compartment biokinetic model for 90 Y-DOTATOC therapy.
Medical physics.
2018 Dec; 45(12):5577-5585. doi:
10.1002/mp.13229. [PMID: 30291717] - Manabu Kadoya, Masafumi Kurajoh, Akio Miyoshi, Takuhito Shoji, Tomonori Terada, Yuji Nakamoto, Yoshitane Tsukamoto, Yuji Moriwaki, Seiichi Hirota, Hidenori Koyama. Ectopic adrenocorticotropic hormone syndrome associated with olfactory neuroblastoma: acquirement of adrenocorticotropic hormone expression during disease course as shown by serial immunohistochemistry examinations.
The Journal of international medical research.
2018 Nov; 46(11):4760-4768. doi:
10.1177/0300060517754026. [PMID: 30392451] - Dieter Hörsch, Samer Ezziddin, Alexander Haug, Klaus Friedrich Gratz, Simone Dunkelmann, Matthias Miederer, Mathias Schreckenberger, Bernd Joachim Krause, Frank M Bengel, Peter Bartenstein, Hans-Jürgen Biersack, Gabriele Pöpperl, R P Baum. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
European journal of cancer (Oxford, England : 1990).
2016 May; 58(?):41-51. doi:
10.1016/j.ejca.2016.01.009. [PMID: 26943056] - C Kratochwil, F L Giesel, F Bruchertseifer, W Mier, C Apostolidis, R Boll, K Murphy, U Haberkorn, A Morgenstern. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
European journal of nuclear medicine and molecular imaging.
2014 Nov; 41(11):2106-19. doi:
10.1007/s00259-014-2857-9. [PMID: 25070685] - Sofie Van Binnebeek, Kristof Baete, Bert Vanbilloen, Christelle Terwinghe, Michel Koole, Felix M Mottaghy, Paul M Clement, Luc Mortelmans, Karin Haustermans, Eric Van Cutsem, Alfons Verbruggen, Kris Bogaerts, Chris Verslype, Christophe M Deroose. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
European journal of nuclear medicine and molecular imaging.
2014 Jun; 41(6):1141-57. doi:
10.1007/s00259-013-2670-x. [PMID: 24668274] - Nicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, Christian Schindler, Michael T Koller, Christoph Rochlitz, Jan Müller-Brand, Helmut R Maecke, Matthias Briel, Martin A Walter. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.
Journal of translational medicine.
2013 Jan; 11(?):17. doi:
10.1186/1479-5876-11-17. [PMID: 23320604] - Harshad R Kulkarni, Christiane Schuchardt, Richard P Baum. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
2013; 194(?):551-9. doi:
10.1007/978-3-642-27994-2_32. [PMID: 22918782] - Christiane Schuchardt, Harshad R Kulkarni, Vikas Prasad, Carolin Zachert, Dirk Müller, Richard P Baum. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
2013; 194(?):519-36. doi:
10.1007/978-3-642-27994-2_30. [PMID: 22918780] - F Guerriero, M E Ferrari, F Botta, F Fioroni, E Grassi, A Versari, A Sarnelli, M Pacilio, E Amato, L Strigari, L Bodei, G Paganelli, M Iori, G Pedroli, M Cremonesi. Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
BioMed research international.
2013; 2013(?):935351. doi:
10.1155/2013/935351. [PMID: 23865075] - Thorsten D Poeppel, Ina Binse, Stephan Petersenn, Harald Lahner, Matthias Schott, Gerald Antoch, Wolfgang Brandau, Andreas Bockisch, Christian Boy. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
2013; 194(?):353-71. doi:
10.1007/978-3-642-27994-2_18. [PMID: 22918768] - Hendrik Bergsma, Esther I van Vliet, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Robin P Peeters, Eric P Krenning, Dik J Kwekkeboom. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Best practice & research. Clinical gastroenterology.
2012 Dec; 26(6):867-81. doi:
10.1016/j.bpg.2013.01.004. [PMID: 23582925] - Clemens Kratochwil, Ruben López-Benítez, Walter Mier, Sabine Haufe, Berend Isermann, Hans-Ulrich Kauczor, Peter L Choyke, Uwe Haberkorn, Frederik L Giesel. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Endocrine-related cancer.
2011 Oct; 18(5):595-602. doi:
10.1530/erc-11-0144. [PMID: 21791571] - Simona Grozinsky-Glasberg, Dganit Barak, Merav Fraenkel, Martin A Walter, Jan Müeller-Brand, Joseph Eckstein, Liat Applebaum, Ilan Shimon, David J Gross. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
Cancer.
2011 Apr; 117(7):1377-85. doi:
10.1002/cncr.25646. [PMID: 21425137] - L Bodei, G Pepe, G Paganelli. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
European review for medical and pharmacological sciences.
2010 Apr; 14(4):347-51. doi:
NULL. [PMID: 20496546] - Hirofumi Hanaoka, Hideyuki Tominaga, Keiich Yamada, Pramila Paudyal, Yasuhiko Iida, Shigeki Watanabe, Bishnuhari Paudyal, Tetsuya Higuchi, Noboru Oriuchi, Keigo Endo. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Annals of nuclear medicine.
2009 Aug; 23(6):559-67. doi:
10.1007/s12149-009-0274-0. [PMID: 19504168] - H Hartmann, K Zöphel, R Freudenberg, L Oehme, M Andreeff, G Wunderlich, G Eisenhofer, J Kotzerke. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
Nuklearmedizin. Nuclear medicine.
2009; 48(5):201-7. doi:
10.3413/nukmed-0214. [PMID: 19639164] - F Forrer, I Riedweg, H R Maecke, J Mueller-Brand. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
2008 Dec; 52(4):334-40. doi:
NULL. [PMID: 18480742] - Raffaella Barone, Stéphan Walrand, Mark Konijnenberg, Roelf Valkema, Larry K Kvols, Eric P Krenning, Stanislas Pauwels, François Jamar. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Nuclear medicine communications.
2008 Mar; 29(3):283-90. doi:
10.1097/mnm.0b013e3282f3d03e. [PMID: 18349800] - Flavio Forrer, Roelf Valkema, Dik J Kwekkeboom, Marion de Jong, Eric P Krenning. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Best practice & research. Clinical endocrinology & metabolism.
2007 Mar; 21(1):111-29. doi:
10.1016/j.beem.2007.01.007. [PMID: 17382268] - Cecilia Hindorf, Sarah Chittenden, Louise Causer, Val J Lewington, Helmut R Mäcke, Glenn D Flux. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
Cancer biotherapy & radiopharmaceuticals.
2007 Feb; 22(1):130-5. doi:
10.1089/cbr.2007.306. [PMID: 17627421] - Yung-Chang Lin, Guang-Uei Hung, Tsai-Yueh Luo, Shih-Chuan Tsai, Shung-Shung Sun, Chien-Chung Hsia, Shu-Ling Chen, Wan-Yu Lin. Reducing renal uptake of 111In-DOTATOC: a comparison among various basic amino acids.
Annals of nuclear medicine.
2007 Jan; 21(1):79-83. doi:
10.1007/bf03034003. [PMID: 17373340] - Yung-Chang Lin, Guang-Uei Hung, Tsai-Yueh Luo, Chun-Hsiung Chen, Chien-Chung Hsia, Shu-Ling Hen, Yung-Jen Ho, Wan-Yu Lin. A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
The Journal of veterinary medical science.
2006 Apr; 68(4):367-71. doi:
10.1292/jvms.68.367. [PMID: 16679728] - Raffaella Barone, Françoise Borson-Chazot, Roelf Valkema, Stéphan Walrand, Franck Chauvin, Lida Gogou, Larry K Kvols, Eric P Krenning, François Jamar, Stanislas Pauwels. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2005 Jan; 46 Suppl 1(?):99S-106S. doi:
NULL. [PMID: 15653658] - Andreas Helisch, Gregor J Förster, Helmut Reber, Hans-Georg Buchholz, Rudolf Arnold, Burkhard Göke, Matthias M Weber, Bertram Wiedenmann, Stanislas Pauwels, Ulrike Haus, Hakim Bouterfa, Peter Bartenstein. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging.
2004 Oct; 31(10):1386-92. doi:
10.1007/s00259-004-1561-6. [PMID: 15175836] - F Forrer, H Uusijärvi, C Waldherr, M Cremonesi, P Bernhardt, J Mueller-Brand, H R Maecke. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging.
2004 Sep; 31(9):1257-62. doi:
10.1007/s00259-004-1553-6. [PMID: 15197500] - Mark W Konijnenberg, Magda Bijster, Eric P Krenning, Marion De Jong. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2004 Jul; 45(7):1260-9. doi:
NULL. [PMID: 15235075] - Lisa Bodei, Marta Cremonesi, Chiara Grana, Paola Rocca, Mirco Bartolomei, Marco Chinol, Giovanni Paganelli. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging.
2004 Jul; 31(7):1038-46. doi:
10.1007/s00259-004-1571-4. [PMID: 15150675] - David Bushnell, Yusuf Menda, Thomas O'Dorisio, Mark Madsen, Sara Miller, Thomas Carlisle, Shayne Squires, Daniel Kahn, Wayne Walkner, Mary Connolly, Sue O'Dorisio, Mark Karwal, James Ponto, Hakim Bouterfa. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Cancer biotherapy & radiopharmaceuticals.
2004 Feb; 19(1):35-41. doi:
10.1089/108497804773391658. [PMID: 15068609] - David Bushnell, Yusuf Menda, Mark Madsen, Thomas O'Dorisio, Thomas Carlisle, Pamela Zehr, Laura Ponto, Mark Karwal, Stan Parker, James Ponto, Mary Connolly, Hakim Bouterfa. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
Cancer biotherapy & radiopharmaceuticals.
2003 Aug; 18(4):581-8. doi:
10.1089/108497803322287664. [PMID: 14503953] - François Jamar, Raffaella Barone, Isabelle Mathieu, Stéphan Walrand, Daniel Labar, Pascal Carlier, Joëlle de Camps, Horst Schran, TianLing Chen, M Charles Smith, Hakim Bouterfa, Roelf Valkema, Eric P Krenning, Larry K Kvols, Stanislas Pauwels. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
European journal of nuclear medicine and molecular imaging.
2003 Apr; 30(4):510-8. doi:
10.1007/s00259-003-1117-1. [PMID: 12582815] - Lisa Bodei, Marta Cremonesi, Stefania Zoboli, Chiara Grana, Mirco Bartolomei, Paola Rocca, Maurizio Caracciolo, Helmut R Mäcke, Marco Chinol, Giovanni Paganelli. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
European journal of nuclear medicine and molecular imaging.
2003 Feb; 30(2):207-16. doi:
10.1007/s00259-002-1023-y. [PMID: 12552338] - Andreas Otte, Markus Cybulla, Stefan M Weiner. 90Y-DOTATOC and nephrotoxicity.
European journal of nuclear medicine and molecular imaging.
2002 Nov; 29(11):1543. doi:
10.1007/s00259-002-0935-x. [PMID: 12537003] - Lisa Bodei, Marco Chinol, Marta Cremonesi, Giovanni Paganelli. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl.
European journal of nuclear medicine and molecular imaging.
2002 Aug; 29(8):1099-1100. doi:
10.1007/s00259-002-0864-8. [PMID: 12296284] - Marion de Jong, Eric Krenning. New advances in peptide receptor radionuclide therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2002 May; 43(5):617-20. doi:
NULL. [PMID: 11994523] - Markus Cybulla, Stefan M Weiner, Andreas Otte. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?.
Medical science monitor : international medical journal of experimental and clinical research.
2002 Apr; 8(4):LE7. doi:
NULL. [PMID: 11951054] - Marco Chinol, Lisa Bodei, Marta Cremonesi, Giovanni Paganelli. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
Seminars in nuclear medicine.
2002 Apr; 32(2):141-7. doi:
10.1053/snuc.2002.31563. [PMID: 11965609] - Andreas Otte, Stefan M Weiner, Markus Cybulla. Is radiation nephropathy caused by yttrium-90?.
Lancet (London, England).
2002 Mar; 359(9310):979; author reply 979. doi:
10.1016/s0140-6736(02)08002-9. [PMID: 11918946] - Tilmann Schumacher, Christian Waldherr, Jan Mueller-Brand, Helmut Maecke. Kidney failure after treatment with 90Y-DOTATOC.
European journal of nuclear medicine and molecular imaging.
2002 Mar; 29(3):435. doi:
10.1007/s00259-001-0720-2. [PMID: 12002721] - Omer Ugur, Paresh J Kothari, Ronald D Finn, Pat Zanzonico, Shutian Ruan, Ilonka Guenther, Helmut R Maecke, Steven M Larson. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Nuclear medicine and biology.
2002 Feb; 29(2):147-57. doi:
10.1016/s0969-8051(01)00290-6. [PMID: 11823119] - Thomas M Behr, Martin Béhé, Gerald Kluge, Martin Gotthardt, Meike L Schipper, Stefan Gratz, Rudolf Arnold, Wolfgang Becker, David M Goldenberg. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
European journal of nuclear medicine and molecular imaging.
2002 Feb; 29(2):277-9. doi:
10.1007/s00259-001-0713-1. [PMID: 11926391] - M Hofmann, H Maecke, R Börner, E Weckesser, P Schöffski, L Oei, J Schumacher, M Henze, A Heppeler, J Meyer, H Knapp. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
European journal of nuclear medicine.
2001 Dec; 28(12):1751-7. doi:
10.1007/s002590100639. [PMID: 11734911] - G J Förster, M J Engelbach, J J Brockmann, H J Reber, H G Buchholz, H R Mäcke, F R Rösch, H R Herzog, P R Bartenstein. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
European journal of nuclear medicine.
2001 Dec; 28(12):1743-50. doi:
10.1007/s002590100628. [PMID: 11734910] - O C Boerman, W J Oyen, F H Corstens. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney.
European journal of nuclear medicine.
2001 Oct; 28(10):1447-9. doi:
10.1007/s002590100597. [PMID: 11688660] - M Cybulla, S M Weiner, A Otte. End-stage renal disease after treatment with 90Y-DOTATOC.
European journal of nuclear medicine.
2001 Oct; 28(10):1552-4. doi:
10.1007/s002590100599. [PMID: 11685499] - C Waldherr, T Schumacher, M Pless, A Crazzolara, H R Maecke, E U Nitzsche, A Haldemann, J Mueller-Brand. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Nuclear medicine communications.
2001 Jun; 22(6):673-8. doi:
10.1097/00006231-200106000-00011. [PMID: 11403179] - S Moll, V Nickeleit, J Mueller-Brand, F P Brunner, H R Maecke, M J Mihatsch. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2001 Apr; 37(4):847-51. doi:
10.1016/s0272-6386(01)80135-9. [PMID: 11273886] - M Cremonesi, M Ferrari, M Chinol, M Bartolomei, M G Stabin, E Sacco, M Fiorenza, G Tosi, G Paganelli. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR).
2000 Dec; 44(4):325-32. doi:
NULL. [PMID: 11302260] - G Paganelli, S Zoboli, M Cremonesi, H R Mäcke, M Chinol. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Cancer biotherapy & radiopharmaceuticals.
1999 Dec; 14(6):477-83. doi:
10.1089/cbr.1999.14.477. [PMID: 10850334] - M Cremonesi, M Ferrari, S Zoboli, M Chinol, M G Stabin, F Orsi, H R Maecke, E Jermann, C Robertson, M Fiorenza, G Tosi, G Paganelli. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
European journal of nuclear medicine.
1999 Aug; 26(8):877-86. doi:
10.1007/s002590050462. [PMID: 10436201] - D J Kwekkeboom, P P Kooij, W H Bakker, H R Mäcke, E P Krenning. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
1999 May; 40(5):762-7. doi:
NULL. [PMID: 10319747] - F Rösch, H Herzog, B Stolz, J Brockmann, M Köhle, H Mühlensiepen, P Marbach, H W Müller-Gärtner. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.
European journal of nuclear medicine.
1999 Apr; 26(4):358-66. doi:
10.1007/s002590050398. [PMID: 10199941] - B F Bernard, E P Krenning, W A Breeman, E J Rolleman, W H Bakker, T J Visser, H Mäcke, M de Jong. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
1997 Dec; 38(12):1929-33. doi:
NULL. [PMID: 9430472] - A Otte, E Jermann, M Behe, M Goetze, H C Bucher, H W Roser, A Heppeler, J Mueller-Brand, H R Maecke. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
European journal of nuclear medicine.
1997 Jul; 24(7):792-5. doi:
10.1007/bf00879669. [PMID: 9211767] - T W Pay, P J Hingley. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines.
Vaccine.
1987 Mar; 5(1):60-4. doi:
10.1016/0264-410x(87)90011-9. [PMID: 3033928] - A A Sharp. Plasma-fibrinogen and thromboemboli after myocardial infarction.
Lancet (London, England).
1977 Jan; 1(8005):251. doi:
10.1016/s0140-6736(77)91040-6. [PMID: 64771]